Background Diseases of early childhood associated with Haemophilus influenzae type b (Hib) can now be prevented by vaccination.
The rapid implementation of routine infant vaccination with Hib polysaccharide-tetanus protein conjugate (PRP-T) vaccine has allowed us to assess whether an accelerated 2,3, and 4 month schedule can protect in the longer term without a booster dose and whether carrier priming influences protective efficacy.
The degree of protection afforded by a catch-up programme with Hib oligosaccharide conjugate (HbOC) for older children was also assessed.
Methods Paediatricians and microbiologists in the UK were asked to report all cases of invasive H influenzae infection in children who had received at least one dose of Hib-conjugate vaccine.
Serum samples from convalescent children were obtained and the isolate was verified.
Efficacy was estimated by comparing observed rates of Hib disease in those who had been vaccinated with rates predicted by age adjustment of disease rates from the prevaccine era.
Findings Of 164 reports of invasive infection between Oct 1,1992, and Oct 1,1995,43 were considered true vaccine failures.
The estimated overall efficacy for three doses of PRP-T was 98.1% (95% Cl 97.3-98.7%). Efficacy in infants aged 5-11 months was 99.1%, 12-23 months 97.3%, and 24-35 months 94.7%. (...)
Mots-clés Pascal : Haemophilus influenzae, Pasteurellaceae, Bactérie, Vaccin associé, Non existence, Surpresseur, Prévention, Facteur risque, Enfant, Homme, Etude comparative, Immunoprophylaxie, Immunopathologie
Mots-clés Pascal anglais : Haemophilus influenzae, Pasteurellaceae, Bacteria, Mixed vaccine, Non existence, Booster, Prevention, Risk factor, Child, Human, Comparative study, Immunoprophylaxis, Immunopathology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0299381
Code Inist : 002B05A02. Création : 15/07/1997.